Regencell Bioscience

RGC

Market cap $15.6B

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 23, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CONTACT THE LAW OFFICES OF H.

New York, New York--(Newsfile Corp. - May 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline. SO WHAT: If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Regencell (RGC) To Contact Him Directly To Discuss Their Options

NEW YORK, May 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"), of the important June 23, 2026 lead plaintiff deadline. So what: If you purchased Regencell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- WHY: New York, N.Y., May 6, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell investors have until June 23, 2026 to file a lead plaintiff motion. IF.

New class action for Regencell (RGC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/23/2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 6, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and reminds investors of the June 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Alert: Claims Focus on Alleged Misrepresentations About Regencell's $1 Million R&D Budget Versus $14 Billion Market Valuation NEW YORK, May 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities of a pending securities class action. THE CASE: A class action was filed, seeking to recover damages for investors who purchased Regencell securities between October 28, 2024 and October 31, 2025.